The Collaborative Research Center 1066 has been funded by the German Research Foundation (DFG) since 2013 and brings together over 50 scientists from various disciplines, including physicians, biologists, and polymer researchers. Our interdisciplinary research consortium consists of highly qualified experts working from basic research in nanomedicine to its application in humans and includes many clinically active physicians who are involved in therapy decisions.

Nanoparticle-based tumor drugs are becoming increasingly important as they enable selective drug delivery and protect the drug from premature degradation. Our research goal is to develop multifunctional nanoparticulate drug carriers for tumor immunotherapy, with a particular focus on malignant melanoma. Many of the research results obtained have the potential for application in humans and can be transferred to the treatment of various types of tumors.